The U.S. food and Drug Administration has approved safety labeling revisions for Bausch & Lomb, Inc.’s  Retisert (a fluocinolone acetonide intravitreal implant). The new labeling includes warnings based on the now available 3-year clinical reports. Use of the product can cause cataracts which require surgical removal in all phakic eyes within an average 3-year period. About 77% of patients will need drugs to lower intraocular pressure (IOP) within this period, and around 37% of patients may require filtering procedures for controlling elevated IOP.